Europe Lyophilized Injectable Drugs Market is expected to grow with the CAGR of 6.3% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:
Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-lyophilized-injectable-drugs-market
Europe lyophilized injectable drugs market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in Europe lyophilized injectable drugs market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in November 2019, Novartis AG announced has signed a strategic agreement with the Medicines Company, the U.S. based pharmaceutical companies. This agreement signed by the company has strengthened its existing innovative medicine product portfolio leading to increased sales and revenue in the market.
Novartis AG is the dominating player in the Europe lyophilized injectable drugs market. The other key players existing in the lyophilized injectable drugs market are Genex Pharma, Aristopharma Ltd., Amneal Pharmaceuticals LLC, Fresenius Kabi Ltd (a subsidiary of Fresenius Kabi AG), Pfizer Inc., Viatris Inc., Gilead Sciences, Inc., Otsuka Pharmaceuticals Co., Ltd. (a subsidiary of Otsuka Holdings Co., Ltd.), Cipla Inc., Cirondrugs, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Sanofi, Celon Laboratories Pvt. Ltd. and Baxter among others.
Novartis AG
Novartis AG is headquartered in Basel, Switzerland and was founded in the year 1996. The company is focusing on developing a broad and consistent pipeline of off-patent launches across key geographies. The company operates its business through two business segments including innovative medicines and sandoz in which innovative medicines is the market focused segment. The company is engaged in manufacturing and marketing of several products under categories including afinitor disperz/votubia, afinitor/votubia, aimovig, arzerra, beovu, cibacen, ciprodex, comtan, cosentyx, diovan, riamet, voltaren/cataflam and xolair among others in which xolair is the market focused category.
For instance,
- In August 2020, Novartis AG received EU approval for Cosentyx indicated for treatment of first line paediatric psoriasis. The drug has been proved highly efficacious in rapidly improving skin symptoms and is available as lyophilized powder in single- use vial. This approval achieved by the company enhanced the company’s product portfolio across Europe and helped it to penetrate its root in Europe lyophilized injectable drugs market.
The company has wide presence across Asia-Pacific, Europe, Middle East and Africa and Americas. The company also has various subsidiary companies including Novartis Pharmaceuticals Canada Inc. (Canada), Beijing Novartis Pharma Co., Ltd (China), Novartis de Colombia S.A. (Colombia), Novartis Pharma NV (Belgium), Sandoz GmbH (Austria) among others.
Cipla Inc.
Cipla Inc. is headquartered in Mumbai, India and was established in the year 1935. The company is engaged in offering advanced pharmaceutical products to meet the needs of people across the globe. The company has two business segments including pharmaceuticals and new ventures in which pharmaceuticals is the market focused segment. The company has several products under categories including respiratory brands and generic products out of which generic products are the market focused category.
For instance,
- In May 2020, Cipla Inc. has launched Cipremi, antiviral medication for COVID-19 patients. According to the company, the medication is in the form of lyophilized powder (freeze dry) for injection of 100 mg.
The company has presence across Americas, Europe, Asia-Pacific and Middle East and Africa. The company also has various subsidiary companies including Cipla BioTec Limited (India), Jay Precision Pharmaceuticals Private Limited (India), Cipla Medpro South Africa (Pty) Limited (South Africa), Cipla Holding B.V. (Netherlands) and Cape to Cairo Exports Proprietary Limited (South Africa) among others.
Pfizer Inc.
Pfizer Inc. is headquartered in New York, U.S. and was founded in the year 1849. The company is focused on providing standard for quality, safety and value in the discovery, development and manufacturing of health care products including innovative medicines and vaccines. The company is engaged in manufacturing of several products including azithromycin, bacitracin, benefix, besponsa, bosulif, caverject, cytarabine, desmopressin acetate, doxorubicin hydrochloride, fludarabine phosphate, gemcitabine, gentamicin sulfate, indomethacin, lidocaine hydrochloride, methotrexate, oxaliplatin, piperacillin and tazobactam, solu-medrol, solu-cortef, vecuronium bromide, vancomycin hydrochloride-, vibramycin monohydrate- doxycycline, zosyn, tygacil, celebrex, chantix, cutaquig, daurismo, duavee, effexor XR, elelyso, eliquis, estring, eucrisa, flector, gel-flow kit, gel-flow NT, ibrance, inflectra, inlyta, lipitor, lorbrena, lyrica, mylotarg, nivestym, nyvepria, octagam 10%, panzyga, premarin, prevnar, pristiq, relpax, retacrit, revatio, ruxience, somavert, sutent, talzenna, tikosyn, torisel, toviaz, trazimera, trumenba, viagra, vizimpro, vyndamax, vyndaqel, xalkori, xeljanz, xtandi, xyntha antihemophilic factor, xyntha solofuse antihemophilic factor, zirabev, zoloft among which azithromycin, bacitracin, benefix, caverject, cytarabine, desmopressin acetate, doxorubicin hydrochloride, fludarabine phosphate, gemcitabine, gentamicin sulfate, indomethacin, lidocaine hydrochloride, methotrexate, oxaliplatin, piperacillin and tazobactam, solu-medrol, solu-cortef, vecuronium bromide, vancomycin hydrochloride-, vibramycin monohydrate- doxycycline, zosyn and tygacil are the market focused products.
For instance,
- In November 2019, Pfizer, Inc. announced that its division, named Upjohn is combined with Mylan N.V. and formed a new company named Viatris, Inc. This combination of the company's business division with Mylan N.V. has increased its product portfolio, leading to increased demand for its product in the market.
The company has presence across Americas, Europe, Middle East and Africa and Asia-Pacific. The company also has various subsidiary companies including Pfizer Animal Health B.V. (Netherlands), Pfizer Asia International B.V. (Netherlands), Pfizer Australia Superannuation Pty Ltd (Australia), Pfizer Dominicana, S.A. (Dominican Republic) and Pfizer Egypt S.A.E. (Egypt) among others.
